Creative Biolabs isolates and screens B. uniformis from stool, intestinal contents or defined consortia using strict anaerobic workflows. Selective media, enrichment strategies and phenotypic screens allow us to recover B. uniformis lineages with desirable traits, such as high SCFA output or barrier-supporting phenotypes, as starting points for downstream characterization.
To confirm that a candidate strain is B. uniformis and distinguish closely related lineages, Creative Biolabs combines 16S rRNA analysis, whole-genome sequencing and comparative genomics. This enables precise species/strain assignment for B. uniformis isolates, along with in-silico assessment of antimicrobial resistance markers and virulence-associated loci to support regulatory and safety evaluations.
The carbohydrate metabolism of B. uniformis is central to its value. Creative Biolabs systematically profiles B. uniformis growth and fermentation on inulin, resistant starch, wheat bran extracts, β-glucans and other oligo-/polysaccharides, quantifying SCFA patterns (acetate, propionate, succinate) and gas production to define “fiber-degrading” and “acid-producing” functional signatures.
To support NGP positioning, we design mechanistic assays that link B. uniformis exposure to barrier integrity, metabolic pathways and inflammatory readouts. High-throughput and customized platforms measure epithelial adhesion, tight-junction preservation, lipid-handling gene expression and bile-acid receptor signalling, building MoA narratives for the most promising B. uniformis strains under realistic physiological conditions.
Direct interaction with the intestinal barrier is crucial for B. uniformis. Creative Biolabs employs Caco-2, HT-29 and mucus-producing co-cultures, as well as gut-on-chip and organoid systems, to evaluate how B. uniformis impacts transepithelial electrical resistance, tight-junction protein expression and mucus layer organization, supporting “barrier-supportive” positioning in preclinical documentation.
Immune modulation is a key differentiator for B. uniformis. Using PBMCs, monocyte-derived dendritic cells and T-cell co-cultures, we quantify how B. uniformis cells, supernatants or purified metabolites shape cytokine profiles (for example IL-10, IL-6, TNF-α) and Treg/Th17 balance, helping to define “immune-balancing” or “anti-inflammatory-leaning” strain archetypes.
Scaling strictly anaerobic bacteria remains challenging. Creative Biolabs establishes robust fermentation processes specifically optimized for B. uniformis, from bench-top reactors to pilot scale. We fine-tune media composition, redox conditions, pH control, carbon source feeds and agitation to sustain viability, productivity and reproducibility, paving the way for later GLP technology transfer.
To support formulation-ready B. uniformis strains, Creative Biolabs develops tailored stabilisation strategies including cryoprotectant screening, lyophilisation and spray-drying optimization, encapsulation options and compatibility with prebiotics or multi-strain consortia. Stability studies under stress and real-time conditions define how B. uniformis maintains viability and functionality across the intended product lifecycle.
